As the world population nears the 8 billion mark, Novartis is celebrating the delivery of 1 billion antimalarial treatments since 1999. That is the equivalent of 1 in 8 people living on our planet!

The RUXCOVID clinical trial highlights the Novartis commitment to leverage our expertise and resources to support the global response to the COVID-19 pandemic.

Learn how we’re working with partners like the International Agency for the Prevention of Blindness to eliminate preventable blindness.

September 29 is World Heart Day. For the past six decades, Novartis has been working to advance heart health around the world.

European Medicines Agency (EMA) recently approved two European Novartis sites for commercial CAR-T manufacturing.

Standing by people with sickle cell disease and their families

As a company, we stand up for greater inclusion of LGBTI people because when each of us feels included, we all benefit.